Author/Editor		Fon-Tacer, Klementina
Title		Hormon stradanja fibroblastni rastni dejavnik 21 - novo zdravilo za debelost in metabolni sindrom?
Translated title		Fasting hormone fibroblast growth factor 21 - new therapy for obesity and metabolic syndrome?
Type		članek
Source		Farm Vestn
Vol. and No.		Letnik 60, št. 5
Publication year		2009
Volume		str. 251-5
Language		slo
Abstract		Increasing prevalence of metabolic diseases is alarming and highlights the need for more effective and safer therapies. Current recommendations for therapy for metabolic syndrome focus on corrections of the individual components. Fibrates are used to treat hyperlipidemia as a predisposing factor to metabolic syndrome and cardiovascular disease. Fibrates mediate their therapeutic effects through the peroxisome proliferator-activated receptor alpha (pPARa). PPARa acts as a transcriptional activator of genes involved in lipolysis and ketone body synthesis. The majority of PPARa effects are mediated by recently discovered starvation hormone - fibroblast growth factor FGF21. Recent evidence from several animal studies indicates that FGF21 induces numerous beneficial metabolic changes without apparent adverse effects. These results suggest that FGF21 could be a novel and attractive drug candidate for the treatment of cardiovascular disease, obesity, and type 2 diabetes.
Descriptors		DIABETES MELLITUS, NON-INSULIN-DEPENDENT HYPERLIPIDEMIA FIBROBLAST GROWTH FACTOR STARVATION OBESITY ENERGY METABOLISM DIETARY FATS